key: cord-0851380-yvqk0h2v authors: Grinspan, Zachary M.; Mytinger, John R.; Baumer, Fiona M.; Ciliberto, Michael A.; Cohen, Bruce H.; Dlugos, Dennis J.; Harini, Chellamani; Hussain, Shaun A.; Joshi, Sucheta M.; Keator, Cynthia G.; Knupp, Kelly G.; McGoldrick, Patricia E.; Nickels, Katherine C.; Park, Jun T.; Pasupuleti, Archana; Patel, Anup D.; Pomeroy, Scott L.; Shahid, Asim M.; Shellhaas, Renee A.; Shrey, Daniel W.; Singh, Rani K.; Wolf, Steven M.; Yozawitz, Elissa G.; Yuskaitis, Christopher J.; Waugh, Jeff L.; Pearl, Phillip L. title: Crisis Standard of Care: Management of Infantile Spasms during COVID‐19 date: 2020-06-08 journal: Ann Neurol DOI: 10.1002/ana.25792 sha: caaca47db42a20baa5666a6153c7799161be6c64 doc_id: 851380 cord_uid: yvqk0h2v The Child Neurology Society collaborated with the Pediatric Epilepsy Research Consortium to issue an online statement April 6, 2020 of immediate recommendations to streamline diagnosis, treatment, and follow up of infantile spasms. The recommendations encourage use of telemedicine, outpatient over inpatient studies, and oral therapies as initial treatment. Each recommendation is earmarked as enduring if intended to outlast the pandemic, and limited if intended only during the duration of the pandemic. This article is protected by copyright. All rights reserved. stay-at-home orders to reduce community transmission. Although COVID-19 infections are milder in children, infants and immunocompromised individuals have the most severe disease among pediatric populations. 5 To balance clinical and public health imperatives, and to respond to urgent questions regarding patient management, the Child Neurology Society collaborated with the Pediatric Epilepsy Research Consortium to issue an online statement April 6, 2020, of immediate recommendations to streamline diagnosis, treatment, and follow-up of infantile spasms. 6 The recommendations encourage use of telemedicine, outpatient over inpatient studies, and oral therapies as initial treatment. Each recommendation is earmarked as enduring if intended to outlast the pandemic, and limited if intended only during the duration of the pandemic. The statement included these enduring recommendations: The initial clinical visit for suspected infantile spasms may be performed by telemedicine or video conference. Parents should be instructed to obtain and share video of several consecutive typical events, to be reviewed prior to or during the initial clinical encounter. The evaluation should include inquiry and observation for light spots on the skin, given the common association of infantile spasms with tuberous sclerosis complex (TSC). EEG confirmation is strongly encouraged and should include at least one sleep-wake cycle, recognizing that epileptiform abnormalities are potentiated by sleep. Hypsarrhythmia may be absent and is not required for the diagnosis. 7 Following diagnosis, if the etiology is uncertain, a magnetic resonance imaging (MRI) is recommended urgently, for example, to diagnose TSC or a structural brain lesion. 8 A genetic evaluation can be high yield, and should also be prioritized. For initial treatment, unless there are contraindications, select from among 3 choices: adrenocorticotropic hormone (ACTH), high dose prednisolone (4-8 mg/kg/ day), and vigabatrin. 9 For TSC, vigabatrin is preferred if immediately available. Otherwise oral prednisolone should be initiated and an echocardiogram obtained. (Hormonal treatments can increase the size of cardiac rhabdomyomas.) Non-standard therapies should be avoided as the first treatment choice for infantile spasms (eg, topiramate, ketogenic diet, and benzodiazepines). For hormonal treatments, gastrointestinal (GI) prophylaxis with a proton pump inhibitor or H2 blocker is recommended with steroid treatment, and a single prescription should include both 2 weeks at a high dose and a 2-week taper. The statement included these limited recommendations: Outpatient EEG is preferred over inpatient admission. The need for inpatient care is driven by the need for rapid and coordinated care, rather than by risk of cardiorespiratory instability or acute neurological decompensation. Initiate treatment with high-dose oral prednisolone in the outpatient setting, other than for TSC. Prednisolone is inexpensive, readily available in commercial pharmacies, and orally administered, in contrast with ACTH and vigabatrin, which require use of subspecialty pharmacies, pre-approval by insurance, and special training of caregivers (ACTH, injections; and vigabatrin, mixing of sachets). High-dose prednisolone regimens (4-8 mg/kg/day) have better response rates than low-dose prednisolone, 10 although the optimal regimen is not established. Follow-up via telehealth at least weekly. If using hormonal therapy, arrange to measure blood pressure at least weekly. Limit laboratory testing to specific indications or clinical concerns. If clinical spasms continue after 7 to 10 days, add or modify treatment without confirmatory EEG. If clinical spasms resolve, or if the caregiver is uncertain, repeat an EEG, including at least one sleep-wake cycle, with preference for outpatient EEG. These recommendations are our crisis standard of care for new onset infantile spasms. The exigency of the current public health crisis demands a fast, effective pivot in how we manage our most vulnerable patients, including a shift to an outpatient-based protocol for both diagnosis and treatment. Heightened concern relates to the utilization of high-dose steroid therapy placing the patients at risk for an iatrogenic immunocompromised state. Our recommendations have appeared to receive widespread acceptance among the child neurology community, functioning within the confines of a new reality, if temporary, of a drastic reduction in availability of hospital-based services. Further study will be needed to assess the impact of these sudden changes. Although enduring recommendations are applicable throughout the pandemic and beyond, limited recommendations are intended for implementation during the time of the pandemic but may be needed for future crises of contagion. Committee on Guidance for Establishing Standards of Care for Use in Disaster Situations Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial Temporal dynamics in viral shedding and transmissibility of COVID-19 Airborne transmission of severe acute respiratory syndrome coronavirus-2 to healthcare workers: a narrative review Epidemiology of COVID-19 among children in China Management of Infantile Spasms during the Covid-19 Pandemic The impact of hypsarrhythmia on infantile spasms treatment response: observational cohort study from the National Infantile Spasms Consortium Infantile spasms: who are the ideal surgical candidates? Summary of recommendations for the management of infantile seizures: task force report for the ILAE Commission of Pediatrics Prednisolone/prednisone as adrenocorticotropic hormone alternative for infantile spasms: a meta-analysis of randomized controlled trials The authors declared no conflict of interest. All authors contributed to conception and design and to drafting the manuscript.